The Peritumor Microenvironment: Physics and Immunity

Overview

Journal Trends Cancer

Publisher Cell Press

Specialty Oncology

Date 2023 May 8

PMID 37156677

Authors

Sue Zhang

Kathryn Regan

Julian Najera

Mark W Grinstaff

Meenal Datta

Hadi T Nia

Affiliations

Soon will be listed here.

Abstract

Cancer initiation and progression drastically alter the microenvironment at the interface between healthy and malignant tissue. This site, termed the peritumor, bears unique physical and immune attributes that together further promote tumor progression through interconnected mechanical signaling and immune activity. In this review, we describe the distinct physical features of the peritumoral microenvironment and link their relationship to immune responses. The peritumor is a region rich in biomarkers and therapeutic targets and thus is a key focus for future cancer research as well as clinical outlooks, particularly to understand and overcome novel mechanisms of immunotherapy resistance.

Citing Articles

Beyond the tumor region: Peritumoral radiomics enhances prognostic accuracy in locally advanced rectal cancer.

Liang Z, Yu M, Yang H, Li H, Xie H, Cui C World J Gastroenterol. 2025; 31(8):99036.

PMID: 40062323 PMC: 11886509. DOI: 10.3748/wjg.v31.i8.99036.

Deep learning model targeting cancer surrounding tissues for accurate cancer diagnosis based on histopathological images.

Li L, Geng Y, Chen T, Lin K, Xie C, Qi J J Transl Med. 2025; 23(1):110.

PMID: 39849586 PMC: 11755804. DOI: 10.1186/s12967-024-06017-6.

Probing the physical hallmarks of cancer.

Nia H, Munn L, Jain R Nat Methods. 2025; .

PMID: 39815103 DOI: 10.1038/s41592-024-02564-4.

Differentiating low- and high-proliferative soft tissue sarcomas using conventional imaging features and radiomics on MRI.

Schmitz F, Voigtlander H, Strauss D, Schlemmer H, Kauczor H, Jang H BMC Cancer. 2024; 24(1):1589.

PMID: 39736582 PMC: 11686906. DOI: 10.1186/s12885-024-13339-7.

Prognostic Value of N1/N2 Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients.

Lang Y, Fu W, Xu W, Ma C, Tian X, Hao C Cancer Med. 2024; 13(24):e70551.

PMID: 39718130 PMC: 11667523. DOI: 10.1002/cam4.70551.

References

Ray A, Callaway M, Rodriguez-Merced N, Crampton A, Carlson M, Emme K . Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma. JCI Insight. 2021; 7(3). PMC: 8855836. DOI: 10.1172/jci.insight.150330. View

Berhouma M, Jacquesson T, Jouanneau E, Cotton F . Pathogenesis of peri-tumoral edema in intracranial meningiomas. Neurosurg Rev. 2017; 42(1):59-71. DOI: 10.1007/s10143-017-0897-x. View

Ramanathan R, McDonough S, Philip P, Hingorani S, Lacy J, Kortmansky J . Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. J Clin Oncol. 2019; 37(13):1062-1069. PMC: 6494359. DOI: 10.1200/JCO.18.01295. View

Hingorani S, Zheng L, Bullock A, Seery T, Harris W, Sigal D . HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2017; 36(4):359-366. DOI: 10.1200/JCO.2017.74.9564. View

Gao X, Wang H, Pollok K, Chen J, Cohen-Gadol A . Activation of death-associated protein kinase in human peritumoral tissue: A potential therapeutic target. J Clin Neurosci. 2015; 22(10):1655-60. DOI: 10.1016/j.jocn.2015.03.044. View

Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Denais C, Gilbert R, Isermann P, McGregor A, Te Lindert M, Weigelin B . Nuclear envelope rupture and repair during cancer cell migration. Science. 2016; 352(6283):353-8. PMC: 4833568. DOI: 10.1126/science.aad7297. View

Del Casar J, Gonzalez L, Alvarez E, Junquera S, Marin L, Gonzalez L . Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat. 2009; 116(1):39-52. DOI: 10.1007/s10549-009-0351-z. View

10.

Xiao Q, Wu J, Wang W, Chen S, Zheng Y, Yu X . DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med. 2018; 24(3):262-270. PMC: 5840007. DOI: 10.1038/nm.4496. View

11.

Leifler K, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J . Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol. 2013; 190(8):4420-30. PMC: 3619527. DOI: 10.4049/jimmunol.1202610. View

12.

Falahat R, Berglund A, Putney R, Perez-Villarroel P, Aoyama S, Pilon-Thomas S . Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A. 2021; 118(15). PMC: 8053941. DOI: 10.1073/pnas.2013598118. View

13.

Kataru R, Ly C, Shin J, Park H, Baik J, Rehal S . Tumor Lymphatic Function Regulates Tumor Inflammatory and Immunosuppressive Microenvironments. Cancer Immunol Res. 2019; 7(8):1345-1358. PMC: 6677612. DOI: 10.1158/2326-6066.CIR-18-0337. View

14.

Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C . Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb). 2015; 7(10):1120-34. PMC: 4593730. DOI: 10.1039/c5ib00040h. View

15.

Miyazawa A, Ito S, Asano S, Tanaka I, Sato M, Kondo M . Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem Biophys Res Commun. 2017; 495(3):2344-2349. DOI: 10.1016/j.bbrc.2017.12.115. View

16.

Polacheck W, Charest J, Kamm R . Interstitial flow influences direction of tumor cell migration through competing mechanisms. Proc Natl Acad Sci U S A. 2011; 108(27):11115-20. PMC: 3131352. DOI: 10.1073/pnas.1103581108. View

17.

Zhao J, Huang F, He F, Gao C, Liang S, Ma P . Forced Activation of Notch in Macrophages Represses Tumor Growth by Upregulating miR-125a and Disabling Tumor-Associated Macrophages. Cancer Res. 2016; 76(6):1403-15. DOI: 10.1158/0008-5472.CAN-15-2019. View

18.

Pickup M, Laklai H, Acerbi I, Owens P, Gorska A, Chytil A . Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res. 2013; 73(17):5336-46. PMC: 3766496. DOI: 10.1158/0008-5472.CAN-13-0012. View

19.

Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D . Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212-7. PMC: 3864274. DOI: 10.1073/pnas.1320318110. View

20.

Elahi-Gedwillo K, Carlson M, Zettervall J, Provenzano P . Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2018; 79(2):372-386. PMC: 6335156. DOI: 10.1158/0008-5472.CAN-18-1334. View